Roflumilast Reduces Cerebral Inflammation in a Rat Model of Experimental Subarachnoid Hemorrhage

Qingjian Wu, Lifeng Qi, Hanxia Li, Leilei Mao, Mingfeng Yang, Rongxia Xie, Xiaoyi Yang, Jian Wang, Zongyong Zhang, Jiming Kong, Baoliang Sun

Research output: Contribution to journalArticle

Abstract

Roflumilast, a selective inhibitor for PDE4, is approved by FDA as an anti-inflammation drug for treatment of chronic obstructive pulmonary disease (COPD). This study investigates the effects of roflumilast on cerebral inflammation in the rat SAH model. Here, we show that subcutaneous administration of roflumilast (3 mg/kg) significantly improved the neurological deficits. Measurement of evans blue extravasation and brain water content revealed a significant reduction of blood-brain barrier permeability and brain edema. Importantly, roflumilast treatment remarkably decreased levels of IL-1β, IL-6, and TNF-α and the number of apoptotic neurons in the brain after SAH. These results indicate that roflumilast is effective in treating cerebral inflammation following SAH.

Original languageEnglish (US)
Pages (from-to)1245-1253
Number of pages9
JournalInflammation
Volume40
Issue number4
DOIs
StatePublished - Aug 1 2017

Fingerprint

Subarachnoid Hemorrhage
Theoretical Models
Inflammation
Phosphodiesterase 4 Inhibitors
Evans Blue
Brain Edema
Brain
Blood-Brain Barrier
Interleukin-1
Chronic Obstructive Pulmonary Disease
Permeability
Interleukin-6
Roflumilast
Neurons
Water
Pharmaceutical Preparations

Keywords

  • cerebral inflammation
  • roflumilast
  • subarachnoid hemorrhage

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Roflumilast Reduces Cerebral Inflammation in a Rat Model of Experimental Subarachnoid Hemorrhage. / Wu, Qingjian; Qi, Lifeng; Li, Hanxia; Mao, Leilei; Yang, Mingfeng; Xie, Rongxia; Yang, Xiaoyi; Wang, Jian; Zhang, Zongyong; Kong, Jiming; Sun, Baoliang.

In: Inflammation, Vol. 40, No. 4, 01.08.2017, p. 1245-1253.

Research output: Contribution to journalArticle

Wu, Q, Qi, L, Li, H, Mao, L, Yang, M, Xie, R, Yang, X, Wang, J, Zhang, Z, Kong, J & Sun, B 2017, 'Roflumilast Reduces Cerebral Inflammation in a Rat Model of Experimental Subarachnoid Hemorrhage', Inflammation, vol. 40, no. 4, pp. 1245-1253. https://doi.org/10.1007/s10753-017-0567-8
Wu, Qingjian ; Qi, Lifeng ; Li, Hanxia ; Mao, Leilei ; Yang, Mingfeng ; Xie, Rongxia ; Yang, Xiaoyi ; Wang, Jian ; Zhang, Zongyong ; Kong, Jiming ; Sun, Baoliang. / Roflumilast Reduces Cerebral Inflammation in a Rat Model of Experimental Subarachnoid Hemorrhage. In: Inflammation. 2017 ; Vol. 40, No. 4. pp. 1245-1253.
@article{c16a3b361e9943d7995b60afa28f8d15,
title = "Roflumilast Reduces Cerebral Inflammation in a Rat Model of Experimental Subarachnoid Hemorrhage",
abstract = "Roflumilast, a selective inhibitor for PDE4, is approved by FDA as an anti-inflammation drug for treatment of chronic obstructive pulmonary disease (COPD). This study investigates the effects of roflumilast on cerebral inflammation in the rat SAH model. Here, we show that subcutaneous administration of roflumilast (3 mg/kg) significantly improved the neurological deficits. Measurement of evans blue extravasation and brain water content revealed a significant reduction of blood-brain barrier permeability and brain edema. Importantly, roflumilast treatment remarkably decreased levels of IL-1β, IL-6, and TNF-α and the number of apoptotic neurons in the brain after SAH. These results indicate that roflumilast is effective in treating cerebral inflammation following SAH.",
keywords = "cerebral inflammation, roflumilast, subarachnoid hemorrhage",
author = "Qingjian Wu and Lifeng Qi and Hanxia Li and Leilei Mao and Mingfeng Yang and Rongxia Xie and Xiaoyi Yang and Jian Wang and Zongyong Zhang and Jiming Kong and Baoliang Sun",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s10753-017-0567-8",
language = "English (US)",
volume = "40",
pages = "1245--1253",
journal = "Inflammation",
issn = "0360-3997",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Roflumilast Reduces Cerebral Inflammation in a Rat Model of Experimental Subarachnoid Hemorrhage

AU - Wu, Qingjian

AU - Qi, Lifeng

AU - Li, Hanxia

AU - Mao, Leilei

AU - Yang, Mingfeng

AU - Xie, Rongxia

AU - Yang, Xiaoyi

AU - Wang, Jian

AU - Zhang, Zongyong

AU - Kong, Jiming

AU - Sun, Baoliang

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Roflumilast, a selective inhibitor for PDE4, is approved by FDA as an anti-inflammation drug for treatment of chronic obstructive pulmonary disease (COPD). This study investigates the effects of roflumilast on cerebral inflammation in the rat SAH model. Here, we show that subcutaneous administration of roflumilast (3 mg/kg) significantly improved the neurological deficits. Measurement of evans blue extravasation and brain water content revealed a significant reduction of blood-brain barrier permeability and brain edema. Importantly, roflumilast treatment remarkably decreased levels of IL-1β, IL-6, and TNF-α and the number of apoptotic neurons in the brain after SAH. These results indicate that roflumilast is effective in treating cerebral inflammation following SAH.

AB - Roflumilast, a selective inhibitor for PDE4, is approved by FDA as an anti-inflammation drug for treatment of chronic obstructive pulmonary disease (COPD). This study investigates the effects of roflumilast on cerebral inflammation in the rat SAH model. Here, we show that subcutaneous administration of roflumilast (3 mg/kg) significantly improved the neurological deficits. Measurement of evans blue extravasation and brain water content revealed a significant reduction of blood-brain barrier permeability and brain edema. Importantly, roflumilast treatment remarkably decreased levels of IL-1β, IL-6, and TNF-α and the number of apoptotic neurons in the brain after SAH. These results indicate that roflumilast is effective in treating cerebral inflammation following SAH.

KW - cerebral inflammation

KW - roflumilast

KW - subarachnoid hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=85018290779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018290779&partnerID=8YFLogxK

U2 - 10.1007/s10753-017-0567-8

DO - 10.1007/s10753-017-0567-8

M3 - Article

C2 - 28451841

AN - SCOPUS:85018290779

VL - 40

SP - 1245

EP - 1253

JO - Inflammation

JF - Inflammation

SN - 0360-3997

IS - 4

ER -